Aav-mediated gene replacement therapy for dsg2-related arvc

Overview

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a challenging condition often leading to severe heart failure and requiring heart transplantation. At Osaka University, researchers have identified a specific genetic cause of ARVC, particularly in Japan, related to DSG2 gene variants. This groundbreaking research proposes an AAV-mediated gene replacement therapy to address the genetic deficiency, offering a novel therapeutic option that could significantly improve patient outcomes and reduce the reliance on heart transplants.

Technical specifications

• Gene Target: DSG2, a desmosome-related gene implicated in ARVC.
• Therapeutic Approach: Utilizes iPSC-derived differentiated cardiomyocytes (iPSC-CMs) for proof of concept.
• Model Validation: Involves DSG2-deficient model mice exhibiting phenotypes similar to human conditions, such as biventricular enlargement and fibrosis.
• Potential Impact: Targets the root genetic cause, potentially reducing arrhythmias and heart failure incidents.

Technology readiness level

This technology is at TRL 3, indicating that active research and proof of concept studies are underway. The team is seeking partnerships with companies experienced in AAV therapy to advance towards clinical applications.